Cowen Maintains Neutral View on Sarepta (SRPT) Despite Rolling NDA for Eteplirsen

Cowen analyst Ritu Baral reiterated a Neutral rating on Sarepta Therapeutic (NASDAQ: SRPT) after the company announced its plans to submit a rolling NDA for eteplirsen shortly after today's pre-NDA meeting with the FDA. SRPT will submit non-clinical and CMC components of the NDA by the end of this week and plans to complete the package mid-year with submission of the clinical module.

"Our talk with SRPT last night leads to us to believe the NDA may be in technical order for filing around then," the analyst said.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $16.38 yesterday.

You May Also Be Interested In

• TD Cowen Resumes EQT Corp. (EQT) at Hold
• London Stock Exchange Group Plc. (LSEG:LN) (LNSTY) PT Raised to GBP88 at HSBC
• TD Cowen Reiterates Buy Rating on Constellation Brands (STZ)